Abstract: A battery pack includes a housing, a set of battery cells, and a latch assembly mechanism. The latch assembly mechanism includes a user activation button that pivots about a first axis and an engaging portion that pivots about a second axis, where the first axis is parallel to the second axis and the user activation button actuates the engaging portion. In another aspect, a battery pack includes a housing and a set of battery cells. The housing includes a top portion, a first side portion connected to the top portion, a second side portion connected to the top portion, the second side portion opposite the first side portion, and a bottom portion connected to the first side portion and the second side portion, the bottom portion opposite the top portion. An insert is molded into at least one of the first side portion and the second side portion.

Abstract: Systems, methods, and storage media for determining the probability of cyber risk-related loss within one or more computing systems composed of computing elements are disclosed. Exemplary implementations may: assess vulnerability by determining an exposure window for a computing element based on the number of discrete times within a given time frame where the computing element is in a vulnerable state; determine a frequency of contact of the computing element with threat actors; normalize the exposure window and the frequency of contact; calculate a threat event frequency by dividing the normalized exposure window by the normalized frequency of contact; and repeat the steps for multiple elements. When combined with liability data that describes the loss magnitude implications of these events ,organizations can prioritize the elements based on loss exposure and take action to prevent loss exposure.

Abstract: Systems, methods, and storage media for determining the probability of cyber risk-related loss within one or more computing systems composed of computing elements are disclosed. Exemplary implementations may: assess vulnerability by determining an exposure window for a computing element based on the number of discrete times within a given time frame where the computing element is in a vulnerable state; determine a frequency of contact of the computing element with threat actors; normalize the exposure window and the frequency of contact; calculate a threat event frequency by dividing the normalized exposure window by the normalized frequency of contact; and repeat the steps for multiple elements. When combined with liability data that describes the loss magnitude implications of these events, organizations can prioritize the elements based on loss exposure and take action to prevent loss exposure.

Abstract: Systems, methods, and storage media for determining the probability of cyber risk-related loss within one or more computing systems composed of computing elements are disclosed. Exemplary implementations may: assess vulnerability by determining an exposure window for a computing element based on the number of discrete times within a given time frame where the computing element is in a vulnerable state; determine a frequency of contact of the computing element with threat actors; normalize the exposure window and the frequency of contact; calculate a threat event frequency by dividing the normalized exposure window by the normalized frequency of contact; and repeat the steps for multiple elements. When combined with liability data that describes the loss magnitude implications of these events, organizations can prioritize the elements based on loss exposure and take action to prevent loss exposure.

Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

Abstract: A method and apparatus useful to sequester sensitive identifiable data from the data associated therewith and store this sensitive data in a shielded limited access structure while the associated data is periodically processed in a data center while concurrently scanned for potential malware/ransomware script. Once thus cleaned the data processed in the data center is then converted to a read only form and as thus converted brought to the limited access structure where it is screened once again for script tags and if none are found is then merged with the corresponding identifiable data to be printed and mailed. This repeated screening pass together with the periodic nature of the data center's operations combine to minimize all potential exposure to unwanted data contamination while the secured nature of the limited access structure can be used for secure long term storage.

Abstract: A method to secure file origination, access and updates between a sender and a receiver is provided.

Abstract: A method for exclusion-based imposter screening is provided. The method includes obtaining a plurality of biometrics related to a payment card owner, wherein the payment card owners owns a payment card. The method also includes, during at least one transaction offer involving the payment card at a point of sale terminal of a seller, obtaining a plurality of biometrics related to a customer entering into the at least one transaction offer. The method also includes comparing the plurality of biometrics related to the payment card owner to the plurality of biometrics related to the customer. The method also includes excluding the customer from the at least one transaction offer if it is determined that the plurality of biometrics related to the customer and the plurality of biometrics related to the payment card owner cannot be from a single person.

Abstract: A method for exclusion-based imposter screening is provided. The method includes detecting a trigger event related to a payment card owned by a payment card owner and requiring the payment card owner to register payment card owner identification data after the trigger event. The method also include, during at least one transaction offer following the trigger event, obtaining customer identification data of a customer entering into the at least one transaction offer and comparing the customer identification data to the payment card owner identification data. The customer is excluded from the at least one transaction offer if it is determined that the customer identification data and the payment card owner identification data cannot be from a single person.

Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4?,3?:4,5]pyrrolo[2,3-d]pyridine, and 9H-1,3,6,9-tetraaza-fluorene compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.

Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.

Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.